KEY POINTSSkin-delivery experiments and safety context
  • The penetration experiment measured copper in isolated skin and collected fluid, not clinical benefit in living participants.
  • A route or formulation change creates a new evidence question; topical findings cannot validate systemic use.

Evidence limit: A copper signal alone does not prove intact GHK-Cu delivery, and route-specific safety concerns need their own evidence.

Overview

The same ingredient name can appear in a laboratory vial, a cosmetic cream and a clinical discussion, but those settings do not share one evidence base. GHK-Cu illustrates the problem. A result from an isolated skin experiment does not establish what a finished cosmetic delivers in everyday use, and a topical study does not establish the effects or safety of systemic exposure. The route and formulation are part of the intervention, rather than details that can be removed from the result.

Delivery research asks where a material goes under specified conditions. Clinical research asks whether a defined intervention produces a relevant benefit or harm in people. Those questions overlap, but a positive answer to the first does not guarantee a positive answer to the second. Detecting copper in tissue, for example, is not the same measurement as detecting an intact active complex at a particular target, and neither by itself demonstrates a cosmetic outcome.

This article explains the boundaries using original skin-penetration research, small topical clinical evidence and the chemical context provided by Echo Peptides’ research guide. It also places the FDA’s concerns about injectable GHK-Cu in their proper scope. The purpose is to help readers recognize when an article changes the tested material, route or outcome along the way. No preparation or administration instructions are provided. The useful conclusion is an evidence map: which questions were examined, which remain uncertain, and what information would be needed before transferring a claim to another product or setting.

VISUAL READING NOTE

The surface is not the whole skin

Formulation at the surfaceStratum corneumThe outer barrier within the epidermisRemaining epidermisDermisDelivery across these layers must be measured.
Conceptual educational diagram. This is a schematic of skin layers, not a microscopy image. It does not show that an ingredient crosses the barrier, remains intact or produces a clinical benefit. Not study data.

Preparing the full guide…

The extended sections are available during your four-minute preview and with free email registration.

  1. A formulation is more than an ingredient list
  2. What the skin-penetration experiment measured
  3. A route change creates a new question
  4. How to read the FDA concern precisely
  5. A checklist for a transferable claim
Full text is served after the reading access check.
REFERENCES

Sources and further reading

Original papers, research background and official guidance are listed below. Check the model, population and application described by each source.

  1. Echo Peptides: GHK-Cu Research GuideEcho hub
  2. Echo Peptides: How to Read a Peptide Certificate of AnalysisEcho hub
  3. Trapaidze et al. (2012): Copper binding to GHK and DAHKOriginal paper
  4. Bossak-Ahmad et al. (2020): Ternary GHK–copper–urocanic-acid complexOriginal paper
  5. Hostynek et al. (2010): Human skin retention and penetration in vitroOriginal paper
  6. Miller et al. (2006): Randomized study after CO2 laser resurfacingOriginal paper
  7. FDA: Bulk Substances That May Present Significant Safety RisksOfficial guidance

This is an educational synthesis, not individual medical advice or a systematic review. Research on a molecule does not establish equivalence, safety or benefit for a supplier’s product.

RELATED READINGWhat is GHK-Cu?GHK-Cu: evidence from topical skin studies